Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Chidamide Combined with a Modified Bu-Cy Conditioning Regimen Improves Survival in Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Xuanqi Cao, Zheng Li, Yanming Zhang, Qingya Cui, Yunju Ma, Mengyun Li, Sifan Chen, Jia Yin, Wei Cui, Jia Chen, Aining Sun, Huiying Qiu, Suning Chen, Zhengming Jin, Xiaming Zhu, De-Pei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 6959.

https://doi.org/10.1182/blood-2023-185258

Published: 2023

Journal Articles

Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia

Sining Liu, Qingya Cui, Zheng Li, Wei Cui, Mengyun Li, Huiying Qiu, Shengli Xue, Suning Chen, Zhengming Jin, Miao Miao, Yue Han, Ying Wang, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 3491.

https://doi.org/10.1182/blood-2023-186718

Published: 2023

Journal Articles

Application of cfDNA-NGS Test in MRD Monitoring of Acute Leukemia Patients with CAR-T Cell Therapy

Juncheng Chen, Qingya Cui, Mengyun Li, Zheng Li, De-Pei Wu, Xiaowen Tang, Hongjie Shen

Blood (2023) 142 (Supplement 1): 2282.

https://doi.org/10.1182/blood-2023-186203

Published: 2023

Journal Articles

Venetoclax+Azacytidine Followed By Modified BuCy Conditioning Regimen for High Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia and High Risk Myelodysplastic Syndromes

QI Tan, Zheng Li, Sifan Chen, Qingya Cui, Mengyun Li, Ye Zhao, Feng Chen, Depei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 4909.

https://doi.org/10.1182/blood-2023-185976

Published: 2023

Journal Articles

Rituximab Improves Clinical Outcomes of CAR-T Therapy for r/r B-ALL Via Sensitizing Leukemia Cells to CAR-T-Mediated Cytotoxicity and Reducing CAR-T Exhaustion

Yangzi Li, Sining Liu, Qingya Cui, Lingling Liu, Zheng Li, Wei Cui, Mengyun Li, Xiaming Zhu, Liqing Kang, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 6803.

https://doi.org/10.1182/blood-2023-184505

Published: 2023

Journal Articles

Anti CD19 CART Therapy Following Allogenic Hematopoietic Stem Cell Transplantation Improved the Survival of Patients with BCR::ABL1 -like Acute Lymphoblastic Leukemia

Haiping Dai, Wei Cui, Hongjie Shen, Qian Wang, Jia Yin, Zheng Li, Depei Wu, Xiaowen Tang

Blood (2022) 140 (Supplement 1): 10345–10346.

https://doi.org/10.1182/blood-2022-166687

Published: 2022

Journal Articles

Disruption of dNTP homeostasis by ribonucleotide reductase hyperactivation overcomes AML differentiation blockade

Blood (2022) 139 (26): 3752–3770.

https://doi.org/10.1182/blood.2021015108

Published: 2022

Includes: Supplemental data

Journal Articles

Tandem CD19/CD22 Dual Targets CAR T-Cells Bridging Hematopoietic Stem Cells Transplantation Acquires Robust Remission for Relapsed and Refractory B Acute Lymphoblastic Leukemia Patients

Wei Cui, Xinyue Zhang, Haiping Dai, Qingya Cui, Jia Yin, Zheng Li, Lei Yu, Liqing Kang, Depei Wu, Xiaowen Tang

Blood (2021) 138 (Supplement 1): 1753.

https://doi.org/10.1182/blood-2021-152565

Published: 2021

Journal Articles

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients

Blood (2021) 138 (Supplement 1): 1755.

https://doi.org/10.1182/blood-2021-152927

Published: 2021

Journal Articles

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Acquires Superior CR Rate Than CD19 CAR-T Cells: A Case Controlled Study

Wei Cui, Xinyue Zhang, Haiping Dai, Qingya Cui, Baoquan Song, Depei Wu, MDPhD, Xiaowen Tang, MD PhD, Jia Yin, Zheng Li

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-143474

Published: 2020

Journal Articles

Repurposing Nelarabine to Induce Differentiation of Acute Myeloid Leukemia

Hanying Wang, Xin He, MD, Feiteng Huang, MS, Haojie Dong, PhD, Wei Chen, PhD, Zheng Li, MS, Jie Sun, PhD, Yinghui Zhu, PhD, Lei Zhang, MD, Yuhui Wu, MD, Lifeng Feng, PhD, Jing Zhang, PhD, Samer Khaled, MD, Guido Marcucci, MD, David Sykes, MD PhD, Hongchuan Jin, MD PhD, Xian Wang, MD PhD, Ling Li, PhD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-139922

Published: 2020

Journal Articles

CD38-Directed CAR-T Cell Therapy: A Novel Immunotherapy Strategy for Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Xiaowen Tang, MD PhD, Depei Wu, MDPhD, Qingya Cui, Chongsheng Qian, Nan Xu, Liqing Kang, Haiping Dai, Baoquan Song, Wei Cui, Jia Yin, Zheng Li, Lei Yu, MD PhD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141602

Published: 2020

Journal Articles

Decitabine As Part of a Modified Bu-Cy Conditioning Regimen Significantly Improved the Outcome of High-Risk AML Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Xiaowen Tang, Benigno C. Valdez, PhD, Qianqian Zhang, Yunju Ma, Haiping Dai, Jia Yin, Zheng Li, Ting Xu, Yang Xu, MD PhD, Jia Chen, Xiaming Zhu, Depei Wu, MD PhD, Borje S Andersson, MD PhD

Blood (2019) 134 (Supplement_1): 3270.

https://doi.org/10.1182/blood-2019-123951

Published: 2019

Journal Articles

Maintenance Therapy with Decitabine after Allogeneic Hematopoietic Stem Cell Transplantation to Prevent Relapse of High Risk Acute Myeloid Leukemia

Yunju Ma, Changju Qu, PhD, Haiping Dai, Jia Yin, Zheng Li, Jia Chen, Huiying Qiu, Aining Sun, PhD, Miao Miao, Chengcheng Fu, Zhengming Jin, MD, Xiaming Zhu, Depei Wu, MD PhD, Xiaowen Tang

Blood (2019) 134 (Supplement_1): 3306.

https://doi.org/10.1182/blood-2019-124033

Published: 2019

Journal Articles

Successful Treatment of Chimeric Antigen Receptor T Cell Therapy in Refractory or Relapsed Acute Leukemia Patients with TP53 alterations

Changju Qu, PhD, Jia Yin, Liqing Kang, Zheng Li, Haiping Dai, Xiaming Zhu, Lei Yu, Depei Wu, MD PhD, Xiaowen Tang

Blood (2019) 134 (Supplement_1): 3822.

https://doi.org/10.1182/blood-2019-128013

Published: 2019

Journal Articles

Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/ Refractory ALL Patients

Xiaowen Tang, Liqing Kang, Wei Qi, Wei Cui, Haiping Dai, Zheng Li, Jia Yin, Changju Qu, PhD, Ting Xu, Xiaming Zhu, Lei Yu, MD PhD, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 1338.

https://doi.org/10.1182/blood-2019-127890

Published: 2019

Journal Articles

Monitoring Voriconazole Pharmacogenomics and Plasma Concentrations in the Treatment and Prevention of Invasive Fungal Disease for Chinese Hematological Patients

XiaoWen Tang, MD, Honglan Qu, Dandan Guo, Ting Xu, Haiping Dai, Zheng Li, Jia Yin, Xiaopeng Tian, Danqing Guo, Yang Xu, MD PhD, Xiaming Zhu, Liyan Miao, Depei Wu, MD

Blood (2017) 130 (Supplement 1): 4827.

https://doi.org/10.1182/blood.V130.Suppl_1.4827.4827

Published: 2017

Journal Articles

MVP Combined with FC As Lymphocyte-Depleting Chemotherapy before CAR-T Treatment Can Reduce the Incidence of Severe Cytokine Release Syndrome for Relapsed/Refractory ALL Patients with High Tumour Burden

XiaoWen Tang, MD, Zheng Li, Ting Xu, Haiping Dai, Jia Yin, Xiaopeng Tian, Shengli Xue, Yang Xu, MD PhD, Xiaming Zhu, Liqing Kang, Yujie Xia, Lei Yu, Depei Wu, MD

Blood (2017) 130 (Supplement 1): 5041.

https://doi.org/10.1182/blood.V130.Suppl_1.5041.5041

Published: 2017

Journal Articles

Expression of MPL in Leukemia Stem Cells and Its Role in Stemness Maintainance

Huan Li, MD, Qing Rao, MS, Pei Yu, MS, Shuying Chen, MD, Zheng Li, MS, Haiyan Xing, Min Wang, MD, Jianxiang Wang

Blood (2016) 128 (22): 1723.

https://doi.org/10.1182/blood.V128.22.1723.1723

Published: 2016

Journal Articles

Combination of Gene Therapy and Nanoparticle Imaging for Improving T-Cell Therapy.

Yoonsu Choi, PhD, Zheng Li, PhD, Xukui Wang, MD, Hui Li, PhD, Feng Li, PhD, Daniel Y Lee, MD, PhD, Parijat Bhatnagar, PhD, Ching H Tung, PhD, Sibani L Biswal, PhD, Dean A. Lee, MD, PhD, King C Li, MD, MBA, Laurence J.N. Cooper, MD, PhD

Blood (2010) 116 (21): 1479.

https://doi.org/10.1182/blood.V116.21.1479.1479

Published: 2010

NARROW

Chidamide Combined with a Modified Bu-Cy Conditioning Regimen Improves Survival in Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia

Application of cfDNA-NGS Test in MRD Monitoring of Acute Leukemia Patients with CAR-T Cell Therapy

Venetoclax+Azacytidine Followed By Modified BuCy Conditioning Regimen for High Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia and High Risk Myelodysplastic Syndromes

Rituximab Improves Clinical Outcomes of CAR-T Therapy for r/r B-ALL Via Sensitizing Leukemia Cells to CAR-T-Mediated Cytotoxicity and Reducing CAR-T Exhaustion

Anti CD19 CART Therapy Following Allogenic Hematopoietic Stem Cell Transplantation Improved the Survival of Patients with BCR::ABL1 -like Acute Lymphoblastic Leukemia

Disruption of dNTP homeostasis by ribonucleotide reductase hyperactivation overcomes AML differentiation blockade

Tandem CD19/CD22 Dual Targets CAR T-Cells Bridging Hematopoietic Stem Cells Transplantation Acquires Robust Remission for Relapsed and Refractory B Acute Lymphoblastic Leukemia Patients

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Acquires Superior CR Rate Than CD19 CAR-T Cells: A Case Controlled Study

Repurposing Nelarabine to Induce Differentiation of Acute Myeloid Leukemia

CD38-Directed CAR-T Cell Therapy: A Novel Immunotherapy Strategy for Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Decitabine As Part of a Modified Bu-Cy Conditioning Regimen Significantly Improved the Outcome of High-Risk AML Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Maintenance Therapy with Decitabine after Allogeneic Hematopoietic Stem Cell Transplantation to Prevent Relapse of High Risk Acute Myeloid Leukemia

Successful Treatment of Chimeric Antigen Receptor T Cell Therapy in Refractory or Relapsed Acute Leukemia Patients with TP53 alterations

Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/ Refractory ALL Patients

Monitoring Voriconazole Pharmacogenomics and Plasma Concentrations in the Treatment and Prevention of Invasive Fungal Disease for Chinese Hematological Patients

MVP Combined with FC As Lymphocyte-Depleting Chemotherapy before CAR-T Treatment Can Reduce the Incidence of Severe Cytokine Release Syndrome for Relapsed/Refractory ALL Patients with High Tumour Burden

Expression of MPL in Leukemia Stem Cells and Its Role in Stemness Maintainance

Combination of Gene Therapy and Nanoparticle Imaging for Improving T-Cell Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only